Drug General Information
Drug ID	D01CPZ
Former ID	DIB003603
Drug Name	ACP-196
Indication	Chronic lymphocytic leukaemia [ICD10:C91]		Phase 3	[525235]
Company	Acerta pharma
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Tyrosine-protein kinase BTK	Target Info	Inhibitor	[550507]
KEGG Pathway	NF-kappa B signaling pathway
	Osteoclast differentiation
	Platelet activation
	B cell receptor signaling pathway
	Fc epsilon RI signaling pathway
	Primary immunodeficiency
PANTHER Pathway	B cell activation
Pathway Interaction Database	Fc-epsilon receptor I signaling in mast cells
	BCR signaling pathway
	FAS (CD95) signaling pathway
	Class I PI3K signaling events
	EPO signaling pathway
PathWhiz Pathway	Fc Epsilon Receptor I Signaling in Mast Cells
Reactome	MyD88:Mal cascade initiated on plasma membrane
	Regulation of actin dynamics for phagocytic cup formation
	DAP12 signaling
	FCERI mediated Ca+2 mobilization
	MyD88 deficiency (TLR2/4)
	IRAK4 deficiency (TLR2/4)
	RHO GTPases Activate WASPs and WAVEs
	Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
WikiPathways	Kit receptor signaling pathway
	MyD88:Mal cascade initiated on plasma membrane
	Signaling by the B Cell Receptor (BCR)
	DAP12 interactions
	B Cell Receptor Signaling Pathway
	TSLP Signaling Pathway
	Regulation of toll-like receptor signaling pathway
	IL-5 Signaling Pathway
References
Ref 525235	ClinicalTrials.gov (NCT02475681) Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL.
Ref 550507	National Cancer Institute Drug Dictionary (drug id 756623).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.